Groundbreaking research has led to the first clinical trial to evaluate the safety of cord blood stem cell treatments for hearing loss. According to a study published in Cell Transplantation, animal subjects treated with cord blood stem cells showed significant healing to the damaged sensory hair cells and neurons in the inner ear. Dr. James Baumgartner, pediatric neurosurgeon, and colleagues at Children’s Memorial Hermann Hospital in Houston will launch the first FDA-regulated clinical trial evaluating the use of cord blood stem cell treatments for children with hearing loss.
The year-long study will follow 10 children, aged six weeks to 18 months, with acquired or congenital (but not genetic) hearing loss. The trial will be selecting only patients who have stored their cord blood with CBR for this trial, to ensure consistency in the stem cell processing, storage and release for infusion.